These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35138412)

  • 1. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larranaga S; Sami A; Hawley S; Judge A; Arden N; Van Staa TP; Cooper C; Abrahamsen B; Javaid MK; Prieto-Alhambra D
    Osteoporos Int; 2022 Jul; 33(7):1579-1589. PubMed ID: 35138412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larrañaga S; Hawley S; Ali MS; Judge A; Arden N; van Staa T; Cooper C; Javaid MK; Prieto-Alhambra D
    Clin Epidemiol; 2018; 10():1417-1431. PubMed ID: 30349390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
    Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
    Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
    Cooper C; Fox KM; Borer JS
    Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis.
    Robinson DE; Ali MS; Pallares N; Tebé C; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey FJ; Cooper C; Dedman D; Delmestri A; Judge A; Pérez-Sáez MJ; Pascual J; Nogues X; Diez-Perez A; Strauss VY; Javaid MK; Prieto-Alhambra D
    J Bone Miner Res; 2021 May; 36(5):820-832. PubMed ID: 33373491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
    Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
    Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance.
    Ali MS; Berencsi K; Marinier K; Deltour N; Perez-Guthann S; Pedersen L; Rijnbeek P; Lapi F; Simonetti M; Reyes C; Van der Lei J; Sturkenboom M; Prieto-Alhambra D
    Osteoporos Int; 2020 Dec; 31(12):2425-2438. PubMed ID: 32757044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study.
    Alarkawi D; Ali MS; Bliuc D; Pallares N; Tebe C; Elhussein L; Caskey FJ; Arden NK; Ben-Shlomo Y; Abrahamsen B; Diez-Perez A; Pascual J; Pérez-Sáez MJ; Center JR; Judge A; Cooper C; Javaid MK; Prieto-Alhambra D
    J Bone Miner Res; 2020 May; 35(5):894-900. PubMed ID: 31968134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
    Svanström H; Pasternak B; Hviid A
    Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.
    Peng YL; Hu HY; Luo JC; Hou MC; Lin HC; Lee FY
    Osteoporos Int; 2014 May; 25(5):1617-23. PubMed ID: 24566586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases.
    Tan EH; Rathod-Mistry T; Strauss VY; O'Kelly J; Giorgianni F; Baxter R; Brunetti VC; Pedersen AB; Ehrenstein V; Prieto-Alhambra D
    J Bone Miner Res; 2024 Aug; 39(7):844-854. PubMed ID: 38619297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial infarction risk among patients with fractures receiving bisphosphonates.
    Pittman CB; Davis LA; Zeringue AL; Caplan L; Wehmeier KR; Scherrer JF; Xian H; Cunningham FE; McDonald JR; Arnold A; Eisen SA
    Mayo Clin Proc; 2014 Jan; 89(1):43-51. PubMed ID: 24388021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
    Vestergaard P
    Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
    Vestergaard P; Schwartz F; Rejnmark L; Mosekilde L
    Osteoporos Int; 2011 Mar; 22(3):993-1001. PubMed ID: 21165600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study.
    Hsiao FY; Hsu WW
    Jpn J Clin Oncol; 2017 Oct; 47(10):935-941. PubMed ID: 28981741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.